bearish
Korean Botox Players in Another Round of Patent Fights: Medytox (086900 KS) Sues Hugel (145020 KS)
308 Views20 Apr 2022 00:51
SUMMARY
- Hugel Inc (145020 KS) dominates South Korean botulinum toxin market, with ~50% share. The company already has presence in China and aims to launch its product in Europe this year.
- Hugel’s ambitious target to enter into the world’s largest botulinum toxin market, U.S. is facing a big obstacle as Medy Tox Inc (086900 KS) filed a complaint against the company.
- Medytox’s U.S. business is uncertain after the ending of its exclusive licensing agreement with Abbvie Inc (ABBV US).
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Hugel: A Solid Turnaround Story With Resumption of Botulax Sales in China27 Jun 2023
- Hugel Inc (145020 KS): Expanding Global Presence Provides Solace Amid Patent Tussle with Competitor27 Jun 2023
- Medy Tox Inc (086900 KS): Legal Battle Continues; Muted Recovery in Export Revenue06 Jul 2022
- Korean Botox Players in Another Round of Patent Fights: Medytox (086900 KS) Sues Hugel (145020 KS)20 Apr 2022
- The Fight to Acquire Hugel - GS Group Led Consortium or Goldman Sachs Led Consortium?15 Aug 2021
- Hugel Placement: A 5.2% Block Deal Sale29 Jun 2020
x